Celmed Oncology (USA), Inc.

Calculating rank

USPTO Granted Patents = 8

% Expired Patents = 100.0

Forward Citations = 17

Loading Chart...

8 inventors (with patents filed for the assignee):

H Michael Shepard (6 out of 60 patents)

Venkata Ramana Doppalapudi (2 out of 45 patents)

Michael P Groziak (2 out of 6 patents)

4. Maria V Sergeeva (2 out of 3 patents)

5. Andrew Vaino (1 out of 7 patents)

6. Carlo Ballatore (1 out of 9 patents)

7. Danielle M Lehsten (1 out of 1 patent)

8. Ming Fai Chan (1 out of 39 patents)

8 patents: Sort by Forward Citations

1. 7605144 - Enzyme catalyzed therapeutic compounds (2009-10-20),

2. 7601703 - Enzyme catalyzed therapeutic agents (2009-10-13),

3. 7465734 - Methods and compositions for overcoming resistance to biologic and chemotherapy (2008-12-16),

4. 7462605 - Phosphoramidate compounds and methods of use (2008-12-09),

5. 7419968 - Methods for treating therapy-resistant tumors (2008-09-02),

6. 7163923 - Peptide deformylase activated prodrugs (2007-01-16),

7. 7138388 - Methods to treat autoimmune and inflammatory conditions (2006-11-21),

8. 7001922 - Peptide deformylase activated prodrugs (2006-02-21),

Company Overview

Celmed Oncology (USA), Inc. is a leading biopharmaceutical company focused on developing innovative cancer treatments. With a strong commitment to research and development, Celmed Oncology is dedicated to improving the lives of cancer patients through cutting-edge therapies. The company's mission is to advance the field of oncology and provide hope to those affected by cancer worldwide.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

8 Patents

#196 in

#1,878 in Canada

CA